IL13RA2 and glioblastoma: Recently, one research has shown that a mesoporous silica nanoparticle (MSN)-based vehicle coated with interleukin-13 receptor subunit alpha-2 (IL13Rα2)-targeted peptide (IP) using polyethylene glycol (PEG) (namely MSN-PEG-IP, MPI) could be utilized as an effective drug delivery system for GBM therapy (Figure 3).